Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Bought first batch last summer with a view for a 2 part buy. Think now is the time for my second purchase, news Imminent and market cap ridiculously low, no funding issues obviously as we have share buy backs. Good luck to us all.
https://twitter.com/mylesmcnulty/status/1570697396358881286?s=46&t=ap7qE3FG7y_EDfNrGHNt2w
https://twitter.com/hackingbutlegal/status/1500465032966062082?s=21 (from 1i1i1i on other board)
t's been a painful year, SP-wise, for @avacta.
From over +150% YTD in March, to 7% down now.
However, my faith in #AVCT gaining legendary status has only grown.
Critical RNSs of 2021:
1) HUA in the EU for AffiDX;
2) First dose escalation for AVA6K.
Both imminent, IMO
The first item will be the catalyst for the commencement of major cash flows for #AVCT.
Having HUA in the EU will facilitate (and accelerate) the granting of HUA in numerous other territories.
The recent independent study will also be a godsend for marketing purposes.
That study demonstrated that AffiDX had 100% sensitivity (up to CT28) and 100% specificity - putting it in the top handful of tests worldwide.
Many countries are phasing out free #COVID19 LFTs. Germany last month, UK to be in Q1.
But COVID-19 is unfortunately here to stay
When people are buying tests themselves (esp. to see older family members), the cream will rise (provided of course that the cream is cost competitive!).
With @Abingdon_Health #ABDX also set to come online for #AVCT any day now, supply can really be ramped up to meet demand
There is also international manufacturing capacity in place (up to 30m a month) - IF @medusa19_ and @avacta can generate sufficient demand.
And of course, there is the rumored proprietary capacity of Medusa itself.????
HUA lands: it all kicks off for #AVCT, I really believe
AVA6K: I think #AVCT is almost at the end of - or has just completed - the 21 observation period, following the third dose of the third patient in C1.
IF all has gone well, dose escalation / commencement of C2 will be a mammoth indicator for both the market and the industry
I know a great many have exited in recent months.
For me, #AVCT right now is a classic example of:
"It's always darkest before the dawn."
The work going on behind the scenes has been immense, I have no doubt.
Buzzing to see how it all plays out in the coming weeks
Posted yesterday by the thread host:
Share Talk, Bulletin Board Heroes: Zak Mir
11/4/2021
"TOOPLE...near-term target 0.17p"
8 min 30 sec:
hTTps://www.share-talk.com/weekend-edition-bulletin-board-heroes-sunday-11th-april-2021/#gs.xzfn6n
Been watching this for a couple of years, finally thought today was right for my entry point, should see some good gains here from a tiny market cap.
If you want a further chat on the company Ring Megan Ray or Tim Blythe on +44 (0) 20 7138 3203, they have responded to me in the past. They are Amur’s Public Relations and you get a better response from them rather than the Nomad.
Myles McNulty today -
There is a real possibility that #AVCT will publish the sensitivity / specificity of its AN-sample LFT before clinical validation even begins, IF the results from the initial testing with clinical samples (ongoing right now) are positive.
This could be within the next two weeks.